Op2Lysis

Executive Summary

Op2Lysis is a French biotechnology company pioneering novel therapies for hemorrhagic stroke, a condition with high mortality and limited treatment options. Founded in 2017 and based in Paris, the company leverages its proprietary NANOp2Lysis® platform to develop OptPA, a thrombolytic agent designed to safely and effectively lyse hematomas and blood clots in the brain. Its lead candidate, O2L-001, aims to address the significant unmet medical need in hemorrhagic stroke management by improving outcomes and reducing disability. The platform's nanoparticle-based delivery system potentially enhances targeting and reduces bleeding risk compared to conventional thrombolytics. With a focus on a devastating neurological emergency, Op2Lysis has the potential to transform standard of care if clinical development succeeds. The company operates in the biologics space and is privately held, with no disclosed funding or valuation. Given the early-stage nature, key upcoming milestones include regulatory submissions, initial clinical data, and financing events that will de-risk the technology and validate its therapeutic approach.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA filing for O2L-00160% success
• Q4 2026Preclinical efficacy data in hemorrhagic stroke models70% success
• H1 2026Series A financing round50% success